161Tb-DOTA-LM3
Combined Beta- Plus Auger Electron Therapy Using a Novel Somatostatin Receptor Subtype 2 Antagonist Labelled With Terbium-161 (161Tb-DOTA-LM3)
Early Phase 1
Recruiting
- Conditions
- Neuroendocrine Neoplasia's (NENs)Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)
- Interventions
- First Posted Date
- 2022-05-03
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- University Hospital, Basel, Switzerland
- Target Recruit Count
- 16
- Registration Number
- NCT05359146
- Locations
- 🇨ðŸ‡
Division of Nuclear Medicine, University Hospital Basel, Basel, Switzerland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath